Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Immunology
Study Phase : Undisclosed
Sponsor : Avacta Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Avacta, Daewoong Form Immunotherapy JV
Details : The joint venture will develop a new class of MSCs that are primed to produce Affimer proteins to enhance the immune-modulatory effect when administered to patients.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
January 08, 2020
Lead Product(s) : Mesenchymal Stem Cell
Therapeutic Area : Immunology
Highest Development Status : Undisclosed
Sponsor : Avacta Group
Deal Size : Undisclosed
Deal Type : Licensing Agreement